GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Common Stock

Vectus Biosystems (ASX:VBS) Common Stock : A$38.37 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Common Stock?

Vectus Biosystems's quarterly common stock increased from Dec. 2022 (A$37.57 Mil) to Jun. 2023 (A$38.35 Mil) and increased from Jun. 2023 (A$38.35 Mil) to Dec. 2023 (A$38.37 Mil).

Vectus Biosystems's annual common stock increased from Jun. 2021 (A$24.84 Mil) to Jun. 2022 (A$27.30 Mil) and increased from Jun. 2022 (A$27.30 Mil) to Jun. 2023 (A$38.35 Mil).

Vectus Biosystems Common Stock Historical Data

The historical data trend for Vectus Biosystems's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Common Stock Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Common Stock
Get a 7-Day Free Trial 17.60 17.86 24.84 27.30 38.35

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.32 27.30 37.57 38.35 38.37

Vectus Biosystems Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines